Axsome Therapeutics (MEX:AZSM) ROCE %: -86.66% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AZSM Axsome Therapeutics Inc MEX:AZSM
52 GF Score
Price MXN1,519.00
GF Value MXN1,494.25
! 1 Warning Sign
View Full Analysis

What is Axsome Therapeutics ROCE %?

Axsome Therapeutics MEX:AZSM 52 ROCE % is -86.66% as of Mar. 2026. GuruFocus rates MEX:AZSM with a GF Score™ of 52/100 and a GF Value™ of MXN1,494.25. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Axsome Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -86.66%.

Axsome Therapeutics  (MEX:AZSM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Axsome Therapeutics ROCE % Related Terms

Axsome Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Axsome Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics ROCE % Chart

Axsome Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -112.10 -118.67 -64.47 -79.69 -50.40

Axsome Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -65.33 -55.33 -60.03 -34.46 -86.66
MEX:AZSM
52GF Score
Axsome Therapeutics Inc MEX:AZSM
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics ROCE % Calculation

Axsome Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-3189.656/( ( (11856.424 - 4798.98) + (12420.422 - 6821.207) )/ 2 )
=-3189.656/( (7057.444+5599.215)/ 2 )
=-3189.656/6328.3295
=-50.40 %

Axsome Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-4569.992/( ( (12420.422 - 6821.207) + (12868.261 - 7920.16) )/ 2 )
=-4569.992/( ( 5599.215 + 4948.101 )/ 2 )
=-4569.992/5273.658
=-86.66 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -86.66% mean?
Axsome Therapeutics (MEX:AZSM) has a ROCE % of -86.66% as of Mar. 2026.
Is Axsome Therapeutics' ROCE % too high?
Axsome Therapeutics' current ROCE % is -86.66%. Overall, Axsome Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' ROCE % compare to MDGL and IONS?
Axsome Therapeutics' ROCE % of -86.66% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Axsome Therapeutics's current ROCE % is -86.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Axsome Therapeutics (MEX:AZSM) has a current ROCE % of -86.66%. The stock's GF Value™ is MXN1,494.25, compared to a current price of MXN1,519.00 — trading 1.7% above its estimated fair value. The current ROCE % is -86.66%. Axsome Therapeutics' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Axsome Therapeutics (MEX:AZSM), the current ROCE % is -86.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (MEX:AZSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of MXN1,519.00 is trading 1.7% above its estimated GF Value™ of MXN1,494.25.

Key valuation signals for MEX:AZSM:

  • ROCE %: -86.66%
  • GF Value™: MXN1,494.25 vs. price of MXN1,519.00 (1.7% above fair value)
  • GF Score™: 52/100 with 1 warning sign

No single metric tells the full story. See the MEX:AZSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for MEX:AZSM

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,519.00
Price
MXN1,494.25
GF Value